These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21365590)

  • 1. [Involvement of vesicular monoamine transporter in attention deficit hyperactivity disorder].
    Lorenzo-Sanz G; Sánchez-Herranz A
    Rev Neurol; 2011 Mar; 52 Suppl 1():S103-8. PubMed ID: 21365590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased platelet vesicular monoamine transporter density in children and adolescents with attention deficit/hyperactivity disorder.
    Toren P; Rehavi M; Luski A; Roz N; Laor N; Lask M; Weizman A
    Eur Neuropsychopharmacol; 2005 Mar; 15(2):159-62. PubMed ID: 15695060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein kinase A affects trafficking of the vesicular monoamine transporters in PC12 cells.
    Yao J; Erickson JD; Hersh LB
    Traffic; 2004 Dec; 5(12):1006-16. PubMed ID: 15522101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The vesicular monoamine transporter 2 contains trafficking signals in both its N-glycosylation and C-terminal domains.
    Yao J; Hersh LB
    J Neurochem; 2007 Mar; 100(5):1387-96. PubMed ID: 17217417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic deletion of vesicular monoamine transporter-2 (VMAT2) reduces dopamine transporter activity in mesencephalic neurons in primary culture.
    Yamamoto H; Kamegaya E; Hagino Y; Imai K; Fujikawa A; Tamura K; Enokiya T; Yamamoto T; Takeshima T; Koga H; Uhl GR; Ikeda K; Sora I
    Neurochem Int; 2007; 51(2-4):237-44. PubMed ID: 17664021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet vesicular monoamine transporter 2 density in the disruptive behavior disorders.
    Zalsman G; Aslanov-Farbstein D; Rehavi M; Roz N; Vermeiren R; Laor N; Weizman A; Toren P
    J Child Adolesc Psychopharmacol; 2011 Aug; 21(4):341-4. PubMed ID: 21851191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons.
    Guillot TS; Miller GW
    Mol Neurobiol; 2009 Apr; 39(2):149-70. PubMed ID: 19259829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered expression of vesicular monoamine transporter 2 in epileptic patients and experimental rats.
    Jiang G; Cao Q; Li J; Zhang Y; Liu X; Wang Z; Guo F; Chen Y; Chen Y; Chen G; Wang X
    Synapse; 2013 Jul; 67(7):415-26. PubMed ID: 23504951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorting of vesicular monoamine transporter 2 to the regulated secretory pathway confers the somatodendritic exocytosis of monoamines.
    Li H; Waites CL; Staal RG; Dobryy Y; Park J; Sulzer DL; Edwards RH
    Neuron; 2005 Nov; 48(4):619-33. PubMed ID: 16301178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic variants in the vesicular monoamine transporter 1 (VMAT1/SLC18A1) and neuropsychiatric disorders.
    Lohoff FW
    Methods Mol Biol; 2010; 637():165-80. PubMed ID: 20419435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of the substrate binding region of vesicular monoamine transporter-2 (VMAT-2) using iodoaminoflisopolol as a novel photoprobe.
    Gopalakrishnan A; Sievert M; Ruoho AE
    Mol Pharmacol; 2007 Dec; 72(6):1567-75. PubMed ID: 17766642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The first luminal domain of vesicular monoamine transporters mediates G-protein-dependent regulation of transmitter uptake.
    Brunk I; Blex C; Rachakonda S; Höltje M; Winter S; Pahner I; Walther DJ; Ahnert-Hilger G
    J Biol Chem; 2006 Nov; 281(44):33373-85. PubMed ID: 16926160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A fluorescent-based assay for live cell, spatially resolved assessment of vesicular monoamine transporter 2-mediated neurotransmitter transport.
    Bernstein AI; Stout KA; Miller GW
    J Neurosci Methods; 2012 Aug; 209(2):357-66. PubMed ID: 22698664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylphenidate normalizes elevated dopamine transporter densities in an animal model of the attention-deficit/hyperactivity disorder combined type, but not to the same extent in one of the attention-deficit/hyperactivity disorder inattentive type.
    Roessner V; Sagvolden T; Dasbanerjee T; Middleton FA; Faraone SV; Walaas SI; Becker A; Rothenberger A; Bock N
    Neuroscience; 2010 Jun; 167(4):1183-91. PubMed ID: 20211696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane-associated vesicles.
    Volz TJ; Farnsworth SJ; King JL; Riddle EL; Hanson GR; Fleckenstein AE
    J Pharmacol Exp Ther; 2007 Nov; 323(2):738-45. PubMed ID: 17693585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of vesicular monoamine transporter (VMAT) 1 and 2 in gastrointestinal endocrine tumours.
    Jakobsen AM; Andersson P; Saglik G; Andersson E; Kölby L; Erickson JD; Forssell-Aronsson E; Wängberg B; Ahlman H; Nilsson O
    J Pathol; 2001 Nov; 195(4):463-72. PubMed ID: 11745679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice.
    Kilbourn MR; Kuszpit K; Sherman P
    Synapse; 2000 Mar; 35(4):250-5. PubMed ID: 10657034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of chronic methylphenidate administration on presynaptic dopaminergic parameters in a rat model for ADHD.
    Simchon Y; Weizman A; Rehavi M
    Eur Neuropsychopharmacol; 2010 Oct; 20(10):714-20. PubMed ID: 20493667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylphenidate HCl: therapy for attention deficit hyperactivity disorder.
    Capp PK; Pearl PL; Conlon C
    Expert Rev Neurother; 2005 May; 5(3):325-31. PubMed ID: 15938665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attention-deficit/hyperactivity disorder and the dopaminergic hypotheses.
    Genro JP; Kieling C; Rohde LA; Hutz MH
    Expert Rev Neurother; 2010 Apr; 10(4):587-601. PubMed ID: 20367210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.